ReviewArthritis research & therapy2003
The role of osteoprotegerin in arthritis.
Review in Arthritis research & therapy, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 29 citations in OpenAlex.
- Large cavernous carotid artery aneurysm with spontaneous thrombosis: is there more to a change in morphology than there seems to be? Illustrative case.Journal of neurosurgery. Case lessons · 2021Article
- Association between serum bone biomarker levels and therapeutic response to abatacept in patients with rheumatoid arthritis (RA): a multicenter, prospective, and observational RA ultrasound cohort study in Japan.BMC musculoskeletal disorders · 2021Observational
- Structural and Functional Changes of Hands and Legs in Early Rheumatoid Arthritis.Medicina (Kaunas, Lithuania) · 2021Article
- Systemic Bone Density at Disease Onset Is Associated With Joint Erosion Progression in Early Naive to Treatment Rheumatoid Arthritis: A Prospective 12-Month Follow-Up Open-Label Study.Frontiers in medicine · 2021Article
- Effects of 1-year anti-TNF-α therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis.Clinical rheumatology · 2020Article
- Polymer conjugation of proteins as a synthetic post-translational modification to impact their stability and activity.Polymer chemistry · 2019Article
- The inhibitory effects of a RANKL-binding peptide on articular and periarticular bone loss in a murine model of collagen-induced arthritis: a bone histomorphometric study.Arthritis research & therapy · 2015Article
- Effect of breastfeeding on serum osteoprotegerin and soluble receptor activator of nuclear factor-kappa B ligand in full term neonates.Iranian Red Crescent medical journal · 2013Article
- Gingival crevicularfluid osteoprotegerin levels in Indian population.Dental research journal · 2012Article
- Differential effects of p38MAP kinase inhibitors on the expression of inflammation-associated genes in primary, interleukin-1beta-stimulated human chondrocytes.British journal of pharmacology · 2010Article
- Emerging treatments for postmenopausal osteoporosis - focus on denosumab.Clinical interventions in aging · 2009Review
- The imbalance between osteoprotegerin and cathepsin K in the serum of patients with longstanding rheumatoid arthritis.Rheumatology international · 2008Article
- Serum osteoprotegerin is increased and independently associated with coronary-artery atherosclerosis in patients with rheumatoid arthritis.Atherosclerosis · 2007Article
- Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis.Rheumatology international · 2005Article
- Serum cathepsin K levels of patients with longstanding rheumatoid arthritis: correlation with radiological destruction.Arthritis research & therapy · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone erosion is a hallmark of rheumatoid arthritis. Recent evidence from experimental arthritis suggests that osteoclasts are essential for the formation of local bone erosions. Two essential regulators of osteoclastogenesis have recently been described: the receptor-activator of nuclear factor kappa B ligand, which promotes osteoclast maturation, and osteoprotegerin (OPG), which blocks osteoclastogenesis. The present review summarizes the current knowledge on the role of osteoclasts in local bone erosion. In addition, the role of OPG as a therapeutic tool to inhibit local bone erosion is addressed. Finally, evidence for OPG as an inhibitor of systemic inflammatory bone loss is discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.